{"filing":{"accession_number":"0001193125-26-338021","cik":"0001061983","ticker":"CYTK","company_name":"CYTOKINETICS INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"cytk-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-20260806.htm"},"events":[{"id":25630,"run_id":23261,"accession_number":"0001193125-26-338021","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Cytokinetics' Q2 2026 financial results, including total revenues of $28.6 million (with $25.3 million from MYQORZO product sales), R\u0026D expenses of $97.8 million, SG\u0026A expenses of $104.4 million, and a net loss of $198.8 million. The press release is furnished as Exhibit 99.1 and includes detailed financial metrics, cash position ($1.7 billion), and updated 2026 guidance, which are material to investors assessing the company's financial performance and runway.","company_name":"CYTOKINETICS INC","ticker":"CYTK","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26514,"accession_number":"0001193125-26-338021","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Cytokinetics' Q2 2026 financial results, including total revenues of $28.6 million (with $25.3 million from MYQORZO product sales), R\u0026D expenses of $97.8 million, SG\u0026A expenses of $104.4 million, and a net loss of $198.8 million. The press release is furnished as Exhibit 99.1 and includes detailed financial metrics, cash position ($1.7 billion), and updated 2026 guidance, which are material to investors assessing the company's financial performance and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:35.352756+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26514,"accession_number":"0001193125-26-338021","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Cytokinetics' Q2 2026 financial results, including total revenues of $28.6 million (with $25.3 million from MYQORZO product sales), R\u0026D expenses of $97.8 million, SG\u0026A expenses of $104.4 million, and a net loss of $198.8 million. The press release is furnished as Exhibit 99.1 and includes detailed financial metrics, cash position ($1.7 billion), and updated 2026 guidance, which are material to investors assessing the company's financial performance and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:35.352756+00:00","company_name":"CYTOKINETICS INC","ticker":"CYTK","filing_date":"2026-08-06"}]}